Akerna Corp
Change company Symbol lookup
Select an option...
KERN Akerna Corp
SLS Sellas Life Sciences Group Inc
DARE Dare Bioscience Inc
POAI Predictive Oncology Inc
CYCC Cyclacel Pharmaceuticals Inc
HTGM HTG Molecular Diagnostics Inc
NBEV New Age Beverages Corp
SAUC Diversified Restaurant Holdings Inc
MYE Myers Industries Inc
AVEO Aveo Pharmaceuticals Inc
Go

Company profile

There is no company profile for KERN.

Price
Delayed
$24.01
Day's Change
0.7705 (3.32%)
Bid
--
Ask
--
B/A Size
--
Day's High
26.00
Day's Low
21.18
Volume
(Heavy Day)

Today's volume of 734,226 shares is on pace to be much greater than KERN's 10-day average volume of 1,018,382 shares.

734,226

UPDATE: Buy the previous 'don't touch' marijuana stock and sell the darling

4:43 pm ET January 11, 2019 (MarketWatch)
Print

By Nigam Arora

A tale of two marijuana stocks -- Aphria and Tilray

(This story was originally published Jan. 10.)

When I first wrote that some investors will make millions in marijuana but many more will lose their shirt, investors had difficulty understanding.

After all, many thought that if marijuana was going to be big, all they had to do was buy a couple of stocks and hold them forever. Now that many investors have experienced volatility in marijuana stocks, and I have published a large number of successful marijuana trades, investors who were previously criticizing me are beginning to understand that it takes knowledge, skill and the proper mindset to make money in marijuana stocks.

When I wrote "How to potentially become a marijuana millionaire, albeit carefully (http://www.marketwatch.com/story/how-to-potentially-become-a-marijuana-millionaire-albeit-carefully-2018-08-27)," the most important word in the headline was "carefully." Let us explore with the help of a chart as to how a previous "don't touch" marijuana stock became a buy.

Chart

Please click here (https://thearorareport.com/chart-analysis-of-marijuana-stock-aphria-apha) for an annotated chart of Aphria (APHA.T). Please note the following:

-- The chart shows when the Arora buy signal was given. Using the Arora Trade Management Guidelines, the average buy price was $4.21. Hindsight shows that the buy signal was given close to the bottom.

-- The position now has a 60% gain in a short time.

-- The chart shows that during the time when there was a lot of bullishness about Aphria, it was a don't-touch stock, per the six screens of the ZYX Change Method.

-- When rumors surfaced that Marlboro maker Altria (MO) would buy Aphria, The Arora Report made a specific call. The call was to not buy Aphria on the rumors. At that time I received many emails questioning that call, especially since The Arora Report is well-known for buying companies that eventually get bought out. To date, 144 of our portfolio companies have been acquired, producing large gains. Please see "Here's an evergreen strategy to make money in a volatile stock market (http://www.marketwatch.com/story/heres-an-evergreen-strategy-to-make-money-in-a-volatile-stock-market-2018-12-17)."

-- Interestingly, The Arora Report made a call to buy marijuana stock Cronos (CRON.T) just before it received a major investment from cigarette maker Altria. This call produced large gains in a very short time.

-- The chart shows that a short-seller report about fraud at Aphria caused the stock to plunge, ultimately providing a buying opportunity.

-- The chart shows that, at the time of the Arora buy signal, sentiment on Aphria had turned extremely negative. Sentiment, at extremes, is a contrary signal. In plain English, this means buy when everybody else turns negative.

-- The chart shows that at the time of Arora buy signal, RSI (relative strength indicator) was oversold. In contrast, RSI is now overbought.

-- The chart shows that at the time of The Arora Report buy signal, RSI was showing a positive divergence. In contrast, RSI is now showing a negative divergence.

-- The chart shows that at the time of the Arora buy signal, volume was very heavy. This indicated that the bottom was most likely in.

-- The chart shows a hostile bid by Green Growth Brands .

The foregoing highlights that Aphria should be bought on a dip into the buy zone. Consider not buying it right here after this run-up. As full disclosure, The Arora Report is taking partial profits to take advantage of this strength. The plan is to either add to the position or start a trade-around position when Aphria dips into the buy zone.

Ask Arora: Nigam Arora answers your questions about investing in stocks, ETFs, bonds, gold and silver, oil and currencies. Have a question? Send it to Nigam Arora (mailto:ask-arora@thearorareport.com).

If you could buy only one marijuana stock

The fact that I am highlighting Aphria does not change the prior recommendation that Canopy Growth (WEED.T) should be the core marijuana position. Please click here (https://thearorareport.com/chart-analysis-of-marijuana-stock-canopy-growth-cgc-tobacco-companies-180909) to see an annotated chart of Canopy Growth. For the sake of full transparency, no changes have been made to this previously published chart. Please see "If you buy only one marijuana stock, this should be it (http://www.marketwatch.com/story/if-you-buy-only-one-marijuana-stock-this-should-be-it-2018-10-05)."

As of this writing, Canopy Growth is experiencing a massive short squeeze, according to the algorithms at The Arora Report. In a short squeeze, investors who previously sold short are either forced to buy to cover their shorts or feel compelled to buy to cover at higher (and higher) prices. Such buying is artificial buying and not real buying based on fundamentals. In the stock market, there are not many things we know with certainty. However, we know with certainty that short squeezes eventually end. When they end, the stock falls. Please see the article on short squeezes in the list below.

Sell (or avoid) the darling

Tilray has been the darling of marijuana investors. As full disclosure, The Arora Report call is to take advantage of the strength to take profits or partial profits depending on the type of investor. We provide guidance for different types of investors.

Even though there is fair probability of Tilray running higher on a potential short squeeze, it is prudent to take profits into this strength because an option lockup is expiring on Jan. 15. Tilray came public with a small float, which has been the root cause of various run-ups in Tilray stock due to short squeezes. After the lockup expiration, there may be selling pressure over a prolonged period and short squeezes may not be as pronounced.

Gain an edge

Segmented money flows have an excellent record in giving investors an edge in all kinds of stocks, not only marijuana stocks. I do credit segmented money flows, in large part, to The Arora Report success in calling moves in various marijuana stocks. To learn about segmented money flows, please see "How 'peak good news' for marijuana stocks may undermine investors (http://www.marketwatch.com/story/how-peak-good-news-for-marijuana-stocks-may-undermine-investors-2018-11-08)." Please click here (https://thearorareport.com/chart-money-flows-cannabis-stocks-11082018) for a previously published chart of segmented money flows on 15 marijuana stocks including Aurora Cannabis (ACB.T), New Age Beverages (NBEV), Constellation Brands (STZ) and marijuana ETF (MJ).

Please also read:

To invest successfully in marijuana stocks, avoid this one thing (http://www.marketwatch.com/story/to-invest-successfully-in-marijuana-stocks-add-this-pointer-to-your-list-of-things-to-do-2018-10-09)

How to survive marijuana stocks' rollercoaster ride (http://www.marketwatch.com/story/how-to-survive-marijuana-stocks-rollercoaster-ride-2018-09-24)

Seven reasons Big Tobacco is likely to make a move on the marijuana industry (http://www.marketwatch.com/story/seven-reasons-why-big-tobacco-is-likely-to-make-a-move-on-the-marijuana-industry-2018-09-10)

Tilray is the poster boy of short-squeeze stock candidates -- here's how to find others (http://www.marketwatch.com/story/tilray-is-the-poster-boy-of-short-squeeze-stock-candidates-heres-how-to-find-others-2018-09-19)

Marijuana beverages are the new thing, but investors should only take sips (http://www.marketwatch.com/story/marijuana-beverages-are-the-new-thing-but-investors-should-only-take-sips-2018-10-02)

Disclosure: Subscribers to The Arora Report (http://thearorareport.com/) may have positions in the securities mentioned in this article or may take positions at any time. Nigam Arora is an investor, engineer and nuclear physicist by background who has founded two Inc. 500 fastest-growing companies. He is the founder of The Arora Report, which publishes four newsletters. Nigam can be reached at Nigam@TheAroraReport.com (mailto:Nigam@TheAroraReport.com).

-Nigam Arora; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

January 11, 2019 16:43 ET (21:43 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.